遗传遗传学：当前研究

抽象的

Triple Negative Breast Cancer – An Overview

Kartik Aysola, Akshata Desai, Crystal Welch, Jingyao Xu, Yunlong Qin, Vaishali Reddy, Roland Matthews, Charlotte Owens, Joel Okoli, Derrick J Beech, Chandrika J Piyathilake, Shyam P Reddy and Veena N Rao

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.